Publicações

Comparative Cost-Effectiveness Analysis of Avelumab plus Axitinib Versus Pembrolizumab plus Axitinib, Ipilimumab plus Nivolumab, and Sunitnib for Advanced Renal Cell Carcinoma in the Uk Perspective

AuthID
P-00S-4K6

Author(s)

De Mello, RA

Ayoub, E

Castelo Branco, P

De Almeida Zia, VAD

Savio, A

Pozza, DH

Tadokoro, H

Teich, N

Tipo de Documento

Abstract

Year published

2020

Publicado

in JOURNAL OF CLINICAL ONCOLOGY, ISSN: 0732-183X

Volume: 38, Número: 6

Conference

Genitourinary Cancers Symposium of the American-Society-Of-Clinical-Oncology (Asco), Date: FEB 13-15, 2020, Location: San Francisco, CA, Patrocinadores: Amer Soc Clin Oncol

Indexing

Wos^®

Metadata
Fontes

Publication Identifiers

Wos: WOS:000529525900692

Source Identifiers

ISSN: 0732-183X

Export Publication Metadata

Lista Marked

Adicionar à lista Marked

Info

At this moment we don't have any links to full text documens.

Comparative Cost-Effectiveness Analysis of Avelumab plus Axitinib Versus Pembrolizumab plus Axitinib, Ipilimumab plus Nivolumab, and Sunitnib for Advanced Renal Cell Carcinoma in the Uk Perspective

Links Úteis

Ajuda

Autenticação Federada (Clique na imagem)

Comparative Cost-Effectiveness Analysis of Avelumab plus Axitinib Versus Pembrolizumab plus Axitinib, Ipilimumab plus Nivolumab, and Sunitnib for Advanced Renal Cell Carcinoma in the Uk Perspective

Links Úteis

Ajuda